AnaptysBio Inc
ANABHealthcare|Biotechnology|USA
$66.46
-0.20 (-0.30%)
Tangible Book
$0.44
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jan 2026
P2
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Nov 2024
P2
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269